Cardiology

Back to articles

Disappointing results for extended-release niacin in the AIM-HIGH trial

KEY POINT

The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial was stopped 18 months early by the National Heart, Lung, and Blood Institute after an analysis of the data showed that adding extended-release niacin (Niaspan—Abbott) to statin therapy in patients with well-controlled LDL cholesterol, low HDL cholesterol, and high triglycerides did not result in a reduction in cardiovascular events.